GLP-1 receptors are not only expressed in the pancreas, but also in peripheral tissues, including the central nervous system, heart, kidney, lung, and gastrointestinal tract [8,9]
We exceed industry standards by subjecting each peptide batch to two comprehensive third-party tests
3,4 American Association of Clinical Endocrinology guidelines recommend treatment with GLP-1RA in T2DM patients with coexisting ASCVD, high-risk for ASCVD, heart failure, or chronic kidney disease regardless of their glycemic control due to their organ protective effects
2-APQC, a small-molecule activator of Sirtuin-3 (SIRT3), alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis